Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies
Treatment of newly-diagnosed diffuse anaplastic Wilms tumors (SAWT) and relapsed favorable histology Wilms tumors (FHWT)
Full IRB Study Title:
AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
IRB Study ID: 2022-183
For complete information, please visit this study on clinicaltrials.gov
Study Sponsor:
Children's Oncology Group
Lead Investigator
Erin Wright, MD
Director, Neuro-Oncology; Director, Shannon E. Wilkes Targeted Therapy Program; Jeffrey A. Barbour Chair for Pediatric Hematology/Oncology Research and Healing; Co-Director, Neurofibromatosis Clinic; Pediatric Neuro-Oncologist
Pediatric Brain Tumor ProgramShowers Family Center for Childhood Cancer and Blood DisordersNeurofibromatosis (NF) Clinic
